1. Home
  2. PFD vs LPTX Comparison

PFD vs LPTX Comparison

Compare PFD & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PFD
  • LPTX
  • Stock Information
  • Founded
  • PFD 1990
  • LPTX 2011
  • Country
  • PFD United States
  • LPTX United States
  • Employees
  • PFD N/A
  • LPTX N/A
  • Industry
  • PFD Investment Managers
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PFD Finance
  • LPTX Health Care
  • Exchange
  • PFD Nasdaq
  • LPTX Nasdaq
  • Market Cap
  • PFD 143.2M
  • LPTX 119.6M
  • IPO Year
  • PFD N/A
  • LPTX N/A
  • Fundamental
  • Price
  • PFD $11.44
  • LPTX $0.30
  • Analyst Decision
  • PFD
  • LPTX Hold
  • Analyst Count
  • PFD 0
  • LPTX 1
  • Target Price
  • PFD N/A
  • LPTX N/A
  • AVG Volume (30 Days)
  • PFD 33.2K
  • LPTX 3.2M
  • Earning Date
  • PFD 01-01-0001
  • LPTX 08-11-2025
  • Dividend Yield
  • PFD 6.30%
  • LPTX N/A
  • EPS Growth
  • PFD N/A
  • LPTX N/A
  • EPS
  • PFD N/A
  • LPTX N/A
  • Revenue
  • PFD N/A
  • LPTX N/A
  • Revenue This Year
  • PFD N/A
  • LPTX N/A
  • Revenue Next Year
  • PFD N/A
  • LPTX N/A
  • P/E Ratio
  • PFD N/A
  • LPTX N/A
  • Revenue Growth
  • PFD N/A
  • LPTX N/A
  • 52 Week Low
  • PFD $8.53
  • LPTX $0.22
  • 52 Week High
  • PFD $11.18
  • LPTX $4.79
  • Technical
  • Relative Strength Index (RSI)
  • PFD 73.12
  • LPTX 37.54
  • Support Level
  • PFD $11.21
  • LPTX $0.27
  • Resistance Level
  • PFD $11.40
  • LPTX $0.32
  • Average True Range (ATR)
  • PFD 0.10
  • LPTX 0.04
  • MACD
  • PFD 0.02
  • LPTX -0.01
  • Stochastic Oscillator
  • PFD 97.73
  • LPTX 16.48

About PFD Flaherty & Crumrine Preferred and Income Fund Incorporated

Flaherty & Crumrine Prefd Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities, which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

Share on Social Networks: